- Companies
NEW YORK, June 6 (Reuters) – Drugmaker Eli Lilly (LLY.N), opens new tab presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss and helping knee pain.
Read more Pfizer’s monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Read more High fuel costs to trigger airline failures and consolidation, industry chief says
Read more Trump faces new Republican resistance in Congress as midterm pressures build
